141 related articles for article (PubMed ID: 17762146)
1. Synergy between verapamil and other multidrug -resistance modulators in model membranes.
Castaing M; Loiseau A; Cornish-Bowden A
J Biosci; 2007 Jun; 32(4):737-46. PubMed ID: 17762146
[TBL] [Abstract][Full Text] [Related]
2. Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge.
Castaing M; Brouant P; Loiseau A; Santelli-Rouvier C; Santelli M; Alibert-Franco S; Mahamoud A; Barbe J
J Pharm Pharmacol; 2000 Mar; 52(3):289-96. PubMed ID: 10757416
[TBL] [Abstract][Full Text] [Related]
3. Effects of cholesterol on dye leakage induced by multidrug-resistance modulators from anionic liposomes.
Castaing M; Loiseau A; Djoudi L
Eur J Pharm Sci; 2003 Jan; 18(1):81-8. PubMed ID: 12554076
[TBL] [Abstract][Full Text] [Related]
4. Thermal dependence of multidrug-resistant-modulator efficiency: a study in anionic liposomes.
Castaing M; Loiseau A; Dani M
J Pharm Pharmacol; 2000 Oct; 52(10):1171-8. PubMed ID: 11092560
[TBL] [Abstract][Full Text] [Related]
5. Designing multidrug-resistance modulators circumventing the reverse pH gradient in tumours.
Castaing M; Loiseau A; Dani M
J Pharm Pharmacol; 2001 Jul; 53(7):1021-8. PubMed ID: 11480537
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.
Sela S; Husain SR; Pearson JW; Longo DL; Rahman A
J Natl Cancer Inst; 1995 Jan; 87(2):123-8. PubMed ID: 7707383
[TBL] [Abstract][Full Text] [Related]
7. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery.
Webb MS; Wheeler JJ; Bally MB; Mayer LD
Biochim Biophys Acta; 1995 Sep; 1238(2):147-55. PubMed ID: 7548129
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin.
Sadasivan R; Morgan R; Fabian C; Stephens R
Cancer Lett; 1991 May; 57(2):165-71. PubMed ID: 1673873
[TBL] [Abstract][Full Text] [Related]
9. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
Belhoussine R; Morjani H; Manfait M
Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
[TBL] [Abstract][Full Text] [Related]
10. A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits.
Santafé J; Martínez de Ibarreta MJ; Segarra J; Melena J; Garrido M
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jul; 354(2):198-204. PubMed ID: 8857598
[TBL] [Abstract][Full Text] [Related]
11. Interactions between verapamil and neutral and acidic liposomes: effects of the ionic strength.
Castaing M; Loiseau A; Mulliert G
Biochim Biophys Acta; 2003 Apr; 1611(1-2):107-14. PubMed ID: 12659951
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance modulator interactions with neutral and anionic liposomes: membrane binding affinity and membrane perturbing activity.
Castaing M; Loiseau A; Mulliert G
J Pharm Pharmacol; 2005 May; 57(5):547-54. PubMed ID: 15901343
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability.
Drori S; Eytan GD; Assaraf YG
Eur J Biochem; 1995 Mar; 228(3):1020-9. PubMed ID: 7737146
[TBL] [Abstract][Full Text] [Related]
14. Proposals for concomitant use of several modulators of multidrug resistance in clinics.
Robert J
Anticancer Res; 1994; 14(6A):2371-3. PubMed ID: 7825974
[TBL] [Abstract][Full Text] [Related]
15. [Experimental study on thermochemotherapy combined with verapamil for reversing the multidrug resistance responsible to breast cancer cell].
Yan X; Hou M; Li SF; Liu YY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):391-3. PubMed ID: 18575322
[TBL] [Abstract][Full Text] [Related]
16. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.
Hill BT; Hosking LK
Cancer Chemother Pharmacol; 1994; 33(4):317-24. PubMed ID: 8281626
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.
Huet S; Chapey C; Robert J
Eur J Cancer; 1993; 29A(10):1377-83. PubMed ID: 8398262
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
19. Comparison of diltiazem and verapamil on rat microvascular permeability.
Taherzadeh M; Warren JB
Microvasc Res; 1997 Nov; 54(3):206-13. PubMed ID: 9441891
[TBL] [Abstract][Full Text] [Related]
20. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
Plumb JA; Wishart GC; Setanoians A; Morrison JG; Hamilton T; Bicknell SR; Kaye SB
Biochem Pharmacol; 1994 Jan; 47(2):257-66. PubMed ID: 8304970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
